Fortunately, a meta-analysis of SGLT2i CVOTs found that diabetic ketoacidosis was rare, occurring in 0.1 to 2.2 per 1,000 person-years in those treated with a SGLT2i, albeit with a significantly greater risk compared to placebo (HR, 2.46
Alkhouri, N
Milliman's experts have diverse actuarial, operational, and market experience from decades in the realm of government healthcare services
Designed for convenient daily use, these fast-absorbing oral drops support appetite regulation, satiety, and healthy metabolic function without the need for injections.* GLP-1/GIP therapy works by supporting pathways involved in appetite control, digestion, insulin response, and energy balance
Semaglutide is a peptide, and peptides degrade when exposed to heat, light, or contamination
Body composition when available